Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Laura Glossner und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Erlangen, Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Friedrich-Alexander University…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Inflammation, Cystadenocarcinoma, Serous, Long Interspersed Nucleotide Elements. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, CLC NIH HHS, Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg (D36).
Abstract (Originalsprache)
High‐grade serous ovarian carcinoma (HGSOC) associates with the worst patient outcome. Understanding the tumor environment in terms of quantifying endogenous retroviruses ( ERVs ) and LINE‐1 expression and their correlations with inflammation genes, checkpoint inhibitors and patient survival is needed. Analysis of 102 treatment‐naïve HGSOC and control tissues for ERVs , LINE‐1 , inflammation and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. One cluster termed Triple‐I with the best patient survival showed the highest number of tumor infiltrating lymphocytes along with 22 overexpressed genes, including CXCL9 and AIM2 . However, Triple‐I associated with the lowest ERV/LINE‐1 expression. The tumor cluster with the second‐best patient survival had both high ERV/LINE‐1 expression and inflammation. Multiplex‐immunohistochemistry revealed CD28 protein solely on immune cells, without co‐expression of the inhibitory CTLA4 receptor. The largest tumor cluster with high ERV/LINE‐1 expression but low inflammation showed a significant low gene expression of the dsRNA sensors MDA5 and RIG‐I supporting an aberrant block in IFN signaling. Our study represents an intrinsic ‘molecular and immunological snapshot’ of the HGSOC tumor environment important for understanding retroelements and inflammation for clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospital Erlangen, Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Germany.
- Department of Physics, Friedrich-Alexander University Erlangen-Nürnberg, Germany.
- Artifact Research, GmbH, Nürnberg, Germany.
- Department of Gynecology and Obstetrics, Laboratory for Molecular Medicine, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, University Hospital Erlangen, Germany.
- Adjunct Affiliation With Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Reiner Strick
Förderung
- NCI NIH HHS
- CLC NIH HHS
- Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg (D36)
- Clinical Center
Zitieren
APA
Glossner, L., Eckstein, M., Mark, C., Beckmann, M. W., Hartmann, A., Strissel, P. L., & Strick, R. (2025). Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70067
Vancouver
Glossner L, Eckstein M, Mark C, Beckmann MW, Hartmann A, Strissel PL, et al. Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer. Molecular Oncology. 2025. doi:10.1002/1878-0261.70067
BibTeX
@article{Glossner2025,
author = {Glossner, Laura and Eckstein, Markus and Mark, Christoph and Beckmann, Matthias W and Hartmann, Arndt and Strissel, Pamela L and Strick, Reiner},
title = {Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70067}
}
EUVIMED